Background. Some endometrial cancers are hormonally dependent. A principal source of
circulating estrogen is conversion of adrenal androstenedione by aromatase. Anastrozole …

Background The clinical benefit rate with aromatase inhibitors and the impact of treatment
on quality of life (QOL) in endometrial cancer is unclear. We report the results of a phase 2 …

OBJECTIVE: To evaluate the efficacy and toxicity of the selective aromatase inhibitor
anastrozole (Arimidex), we conducted a phase II trial in 53 women with asymptomatic …

Purpose: Treatment for patients with recurrent endometrioid endometrial cancer (EEC) are
limited as paclitaxel is the only second-line chemotherapy with a response rate> 13 …

OBJECTIVE: The goal of this study was to determine response rate and evaluate toxicity of
LY353381 (arzoxifene) in patients with recurrent or advanced endometrial cancer (EC) …

PURPOSE: In two large Gynecologic Oncology Group studies of patients with advanced or
recurrent endometrial carcinoma and no previous systemic therapy, progestins have …

OBJECTIVES: To evaluate the response rate and progression free and overall survival of
patients with advanced endometrial cancer treated with paclitaxel, carboplatin and …

OBJECTIVE.: A phase II study was conducted to determine the efficacy of oxaliplatin therapy
in patients with advanced or recurrent endometrial cancer who had received one prior …

OBJECTIVE: Endometrial carcinoma is the most common malignancy of the female
reproductive tract. Most cases are diagnosed at an early stage due to the appearance of …

Purpose The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in
endometrial cancer (EC). Hormonal manipulation leads to response in some patients with …